Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

568 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Breast-cancer adjuvant therapy with zoledronic acid.
Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ, Ritchie D, Pugh J, Gaunt C, Rea U, Peterson J, Davies C, Hiley V, Gregory W, Bell R; AZURE Investigators. Coleman RE, et al. Among authors: gregory w. N Engl J Med. 2011 Oct 13;365(15):1396-405. doi: 10.1056/NEJMoa1105195. Epub 2011 Sep 25. N Engl J Med. 2011. PMID: 21995387 Free article. Clinical Trial.
Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial.
Coleman R, Hall A, Albanell J, Hanby A, Bell R, Cameron D, Dodwell D, Marshall H, Jean-Mairet J, Tercero JC, Rojo F, Gregory W, Gomis RR. Coleman R, et al. Among authors: gregory w. Lancet Oncol. 2017 Nov;18(11):1543-1552. doi: 10.1016/S1470-2045(17)30603-4. Epub 2017 Oct 13. Lancet Oncol. 2017. PMID: 29037984 Free article. Clinical Trial.
Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial.
Brown J, Rathbone E, Hinsley S, Gregory W, Gossiel F, Marshall H, Burkinshaw R, Shulver H, Thandar H, Bertelli G, Maccon K, Bowman A, Hanby A, Bell R, Cameron D, Coleman R. Brown J, et al. Among authors: gregory w. J Natl Cancer Inst. 2018 Aug 1;110(8):871-879. doi: 10.1093/jnci/djx280. J Natl Cancer Inst. 2018. PMID: 29425304 Free PMC article. Clinical Trial.
Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial.
Bird S, Cairns D, Menzies T, Boyd K, Davies F, Cook G, Drayson M, Gregory W, Jenner M, Jones J, Kaiser M, Owen R, Jackson G, Morgan G, Pawlyn C. Bird S, et al. Among authors: gregory w. Clin Lymphoma Myeloma Leuk. 2021 Oct;21(10):667-675. doi: 10.1016/j.clml.2021.04.013. Epub 2021 Apr 24. Clin Lymphoma Myeloma Leuk. 2021. PMID: 34059488 Free PMC article. Clinical Trial.
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.
Brown JE, Royle KL, Gregory W, Ralph C, Maraveyas A, Din O, Eisen T, Nathan P, Powles T, Griffiths R, Jones R, Vasudev N, Wheater M, Hamid A, Waddell T, McMenemin R, Patel P, Larkin J, Faust G, Martin A, Swain J, Bestall J, McCabe C, Meads D, Goh V, Min Wah T, Brown J, Hewison J, Selby P, Collinson F; STAR Investigators. Brown JE, et al. Among authors: gregory w. Lancet Oncol. 2023 Mar;24(3):213-227. doi: 10.1016/S1470-2045(22)00793-8. Epub 2023 Feb 13. Lancet Oncol. 2023. PMID: 36796394 Free article. Clinical Trial.
Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial.
Schey S, Brown SR, Tillotson AL, Yong K, Williams C, Davies F, Morgan G, Cavenagh J, Cook G, Cook M, Orti G, Morris C, Sherratt D, Flanagan L, Gregory W, Cavet J; Myeloma UK Early Phase Clinical Trial Network. Schey S, et al. Among authors: gregory w. Br J Haematol. 2015 Aug;170(3):336-48. doi: 10.1111/bjh.13435. Epub 2015 Apr 20. Br J Haematol. 2015. PMID: 25891006 Free article. Clinical Trial.
The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma.
Brown S, Hinsley S, Ballesteros M, Bourne S, McGarry P, Sherratt D, Flanagan L, Gregory W, Cavenagh J, Owen R, Williams C, Kaiser M, Low E, Yong K; Myeloma UK Clinical Trials Network. Brown S, et al. Among authors: gregory w. BMC Hematol. 2016 May 17;16:14. doi: 10.1186/s12878-016-0053-9. eCollection 2016. BMC Hematol. 2016. PMID: 27190631 Free PMC article.
568 results